Telo, GSK targeting TERT to halt glioblastoma cell immortality

Telo Therapeutics Inc. (San Francisco, Calif.) is exploiting a partnership with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to discover small molecules against an isoform of GABPB1, first identified as a cancer immortality target

Read the full 318 word article

User Sign In